102 related articles for article (PubMed ID: 16945059)
1. Probable association between ziprasidone and worsening hypertension.
Villanueva N; Markham-Abedi C; McNeely C; Diaz FJ; de Leon J
Pharmacotherapy; 2006 Sep; 26(9):1352-7. PubMed ID: 16945059
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone-associated depressive state in schizophrenic patients.
Kaptsan A; Dwolatzky T; Lerner V
Clin Neuropharmacol; 2007; 30(6):357-61. PubMed ID: 18090461
[TBL] [Abstract][Full Text] [Related]
3. High-dose ziprasidone-induced acute dystonia.
Rosenfield PJ; Girgis RR; Gil R
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):546-7. PubMed ID: 17123682
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
Ozen ME; Yumru M; Savas HA; Cansel N; Herken H
World J Biol Psychiatry; 2007; 8(1):42-4. PubMed ID: 17366349
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Ku HL; Su TP; Chou YH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone as a possible cause of cleft palate in a newborn.
Peitl MV; Petrić D; Peitl V
Psychiatr Danub; 2010 Mar; 22(1):117-9. PubMed ID: 20305605
[TBL] [Abstract][Full Text] [Related]
7. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
8. Urticaria and angio-oedema due to ziprasidone.
Akkaya C; Sarandol A; Aydogan K; Kirli S
J Psychopharmacol; 2007 Jul; 21(5):550-2. PubMed ID: 17446198
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of ziprasidone: an expanding perspective.
Daniel DG
J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
[TBL] [Abstract][Full Text] [Related]
11. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
12. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.
Eker SS; Sarandol A; Akkaya C; Sivrioglu EY; Kirli S
J Psychopharmacol; 2009 Nov; 23(8):993-6. PubMed ID: 18635710
[TBL] [Abstract][Full Text] [Related]
13. [Risk of QTc prolongation due to combination of ziprasidone and quetiapine].
Minov C
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S142-4. PubMed ID: 15570533
[TBL] [Abstract][Full Text] [Related]
14. Acute dystonia after initial doses of ziprasidone: a case report.
Yumru M; Savas HA; Selek S; Savas E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):745-7. PubMed ID: 16580766
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone- and lithium-induced neuroleptic malignant syndrome.
Borovicka MC; Bond LC; Gaughan KM
Ann Pharmacother; 2006 Jan; 40(1):139-42. PubMed ID: 16352776
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone-induced galactorrhea: a case report.
Kopecek M; Bares M; Mohr P
Neuro Endocrinol Lett; 2005 Feb; 26(1):69-70. PubMed ID: 15726024
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient.
Tsai CF; Tsai SJ; Hwang JP
Int J Geriatr Psychiatry; 2005 Aug; 20(8):797-9. PubMed ID: 16035110
[No Abstract] [Full Text] [Related]
18. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
[TBL] [Abstract][Full Text] [Related]
19. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
Mistry GC; Maes AL; Lasseter KC; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
J Clin Pharmacol; 2008 May; 48(5):592-8. PubMed ID: 18353996
[TBL] [Abstract][Full Text] [Related]
20. A patient using ziprasidone with polydipsia, seizure, hyponatremia and rhabdomyolysis.
Akkaya C; Sarandol A; Sivrioglu EY; Kotan Z; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1535-8. PubMed ID: 16820256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
